Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Part B Average Sales Price Reporting Would Change Under CMS Proposal

This article was originally published in The Pink Sheet Daily

Executive Summary

The proposal would stipulate the inclusion of wholesale acquisition costs in ASP data collection.

You may also be interested in...



Average Sales Price Formula Closely Follows Medicare Rx Law

The ASP final rule is scheduled to be published in the Federal Register April 6. CMS notes that the methodology may change in future years to include further price concessions.

Part D Enrollment Deadline Approaches With Fewer Than 6 Mil. Eligibles Still Unenrolled

The federal government is on the verge of ensuring that 90% of Medicare-eligible people receive prescription drug coverage, HHS Secretary Leavitt said.

GSK Takes Cue From Schering Patient Assistance Program, Seeks Opinion From OIG

HHS Office of Inspector General will decide whether GlaxoSmithKline can donate medicines to Part D-enrolled patients.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS062749

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel